KLK2 and prostate cancer: Transcript analysis of additional prototypical AR‐regulated genes FKBP5, KLK2, NKX3.1, and TMPRSS2 shows a similar pattern of expression to PSA and Ki67 (Fig. 3E), indicating general inhibition of androgen signaling by bicalutamide in prostate cancer PDEs.